NCT05309850 Primary Prevention With the Lifestyle Tool
| NCT ID | NCT05309850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Cardiovascular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 90,000 participants |
| Start Date | 2022-04-05 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90,000 participants in total. It began in 2022-04-05 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes and cardiovascular disease in those using the tool regularly and those in the control group.
Eligibility Criteria
Inclusion Criteria: * informed consent * Age above 35 years Exclusion Criteria: * type 1 diabetes, MODY or secondary diabetes * conditions or treatments that in the judgement of the Investigator could affect the study evaluation * connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.
Contact & Investigator
Anders Rosengren
PRINCIPAL INVESTIGATOR
Göteborg University
Frequently Asked Questions
Who can join the NCT05309850 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05309850 currently recruiting?
Yes, NCT05309850 is actively recruiting participants. Contact the research team at birgitta.x.abrahamsson@skane.se for enrollment information.
Where is the NCT05309850 trial being conducted?
This trial is being conducted at Malmö, Sweden.
Who is sponsoring the NCT05309850 clinical trial?
NCT05309850 is sponsored by Region Skane. The principal investigator is Anders Rosengren at Göteborg University. The trial plans to enroll 90,000 participants.